Viyash Scientific Ltd. (VIYASH) fundamentals
Viyash Scientific Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as VIYASH (ISIN INE807F01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Viyash Scientific Ltd. does
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Valuation and market data
| Last close | ₹257.60 |
|---|---|
| Market capitalisation | ₹14,149 crore |
| Enterprise value | ₹14,461 crore |
| P/E (TTM) | 62.98 |
| Price to book | 4.54 |
| Price to sales (TTM) | 2.32 |
| Book value per share | ₹56.71 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Mar 10 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹3,464 crore | ₹349 crore | ₹225 crore | 4.09 |
| Mar 2025 | ₹3,040 crore | ₹13 crore | ₹16 crore | 0.54 |
| Mar 2024 | ₹1,381 crore | ₹-55 crore | ₹-30 crore | -1.44 |
| Mar 2023 | ₹1,427 crore | ₹-138 crore | ₹-122 crore | -4.88 |
| Mar 2022 | ₹1,424 crore | ₹53 crore | ₹45 crore | 1.66 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 61.3% |
|---|---|
| Foreign institutions (FII) | 4.5% |
| Mutual funds | 2.9% |
| Other domestic institutions | 0.8% |
| Retail and others | 30.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.